Literature DB >> 3036369

Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.

J Tanner, J Weis, D Fearon, Y Whang, E Kieff.   

Abstract

The type 2 complement receptor, CR2, a B lymphocyte surface glycoprotein, is known to be a component of the EBV receptor. We now demonstrate that the major EBV outer membrane glycoprotein, gp350/220, is a highly specific ligand for CR2. EBV or beads coated with purified recombinant gp350/220 adsorb to normal B lymphocytes, cap with CR2, become endocytosed into vesicles, and are released into the cytoplasm. This is the first demonstration of herpesvirus glycoprotein-cell glycoprotein receptor interaction in viral adsorption and penetration. The capping of CR2 in response to virus, gp350/220-coated beads, or anti-CR2 monoclonal antibodies is associated with cocapping of surface immunoglobulin. Interaction between CR2 and surface immunoglobulin may be important in modulating the B cell activation that normally follows EBV infection or exposure to antigen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036369     DOI: 10.1016/0092-8674(87)90216-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  165 in total

1.  Identification of human herpesvirus 8-specific cytotoxic T-cell responses.

Authors:  M Osman; T Kubo; J Gill; F Neipel; M Becker; G Smith; R Weiss; B Gazzard; C Boshoff; F Gotch
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Analysis of Epstein-Barr virus (EBV) receptor CD21 on peripheral B lymphocytes of long-term EBV- adults.

Authors:  W J Jabs; M Paulsen; H J Wagner; H Kirchner; H Klüter
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

3.  Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes.

Authors:  V Omelyanenko; P Kopecková; R K Prakash; C D Ebert; J Kopecek
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

4.  Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.

Authors:  K M Haan; W W Kwok; R Longnecker; P Speck
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Epstein-Barr virus enters B cells and epithelial cells by different routes.

Authors:  N Miller; L M Hutt-Fletcher
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

7.  Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.

Authors:  Susan M Turk; Ru Jiang; Liudmila S Chesnokova; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

8.  Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.

Authors:  R S Haddad; L M Hutt-Fletcher
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  gp96 Is Critical for both Human Herpesvirus 6A (HHV-6A) and HHV-6B Infections.

Authors:  Jingjing Ma; Junli Jia; Xuefeng Jiang; Mengyuan Xu; Jinfeng Guo; Tian Tang; Xianyi Xu; Zhisheng Wu; Benshun Hu; Kun Yao; Lingyun Li; Huamin Tang
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

10.  The lytic cycle of Epstein-Barr virus in the nonproducer Raji line can be rescued by the expression of a 135-kilodalton protein encoded by the BALF2 open reading frame.

Authors:  G Decaussin; V Leclerc; T Ooka
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.